- Home
- XERS vs LKFT Comparison
XERS vs LKFT Comparison
Compare XERS & LKFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | LKFT |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | XERS | LKFT |
|---|---|---|
| Price | $13.32 | $34.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 6 |
| Target Price | $12.86 | ★ $30.31 |
| AVG Volume (30 Days) | ★ 2.2M | 234.3K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $32.91 | N/A |
| Revenue Next Year | $23.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $5.25 | $25.68 |
| 52 Week High | $11.42 | $34.13 |
Technical Indicators
Market Signals| Indicator | XERS | LKFT |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 77.34 |
| Support Level | $9.73 | $28.50 |
| Resistance Level | $10.60 | N/A |
| Average True Range (ATR) | 0.48 | 0.68 |
| MACD | -0.09 | 0.21 |
| Stochastic Oscillator | 39.36 | 99.16 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About LKFT Lakefront Biotherapeutics American Depositary Shares
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.